Trial Profile

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix or NeisVac-C in Healthy Toddlers 12 to 23 Months of Age

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate
Indications Meningococcal group C infections
Focus Pharmacodynamics; Registrational
Sponsors Sanofi Pasteur

Most Recent Events

10 Jul 2021 According to a Sanofi media release, full results will be submitted for publication in a peer-reviewed journal Q4 2021.
10 Jul 2021 According to a Sanofi media release, results from this trial were presented in an oral session at the 2021 European Congress of Clinical Microbiology and Infectious Disease.
10 Jul 2021 Results published in the Sanofi Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com